Fox Run Management L.L.C. Invests $660,000 in InMode Ltd. (NASDAQ:INMD)

Fox Run Management L.L.C. purchased a new stake in shares of InMode Ltd. (NASDAQ:INMD) in the 4th quarter, Holdings Channel reports. The fund purchased 39,502 shares of the healthcare company’s stock, valued at approximately $660,000.

A number of other hedge funds also recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans bought a new stake in shares of InMode in the 3rd quarter worth $201,000. Intech Investment Management LLC purchased a new stake in shares of InMode during the third quarter valued at $526,000. D.A. Davidson & CO. increased its holdings in InMode by 10.5% in the 3rd quarter. D.A. Davidson & CO. now owns 41,278 shares of the healthcare company’s stock worth $700,000 after buying an additional 3,915 shares in the last quarter. Quantbot Technologies LP purchased a new position in InMode in the 3rd quarter worth about $1,104,000. Finally, Townsquare Capital LLC bought a new position in InMode during the 3rd quarter valued at about $202,000. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Stock Up 2.0 %

NASDAQ INMD opened at $19.00 on Tuesday. The company has a 50-day moving average price of $18.19 and a 200-day moving average price of $17.73. InMode Ltd. has a 52 week low of $14.87 and a 52 week high of $21.92. The firm has a market capitalization of $1.32 billion, a P/E ratio of 8.09 and a beta of 2.08.

Analyst Ratings Changes

INMD has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research note on Tuesday, February 4th. Barclays lifted their target price on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $22.25.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.